Sharps Technology, Inc. (STSS)
NASDAQ: STSS · Real-Time Price · USD
2.460
-0.200 (-7.52%)
At close: Dec 5, 2025, 4:00 PM EST
2.490
+0.030 (1.22%)
After-hours: Dec 5, 2025, 7:08 PM EST

Company Description

Sharps Technology, Inc., a medical device and pharmaceutical packaging company, engages in the design, research and development, manufacturing, and commercialization of safety syringe products in the United States.

The company provides safety syringe products comprising Securgard, Sologard, and Sharps Provensa that are ultra-low waste syringes for passive, and safety and reuse prevention features, as well as develops prefillable syringe systems.

The company was incorporated in 2017 and is based in Melville, New York.

Sharps Technology, Inc.
Sharps Technology logo
Country United States
Founded 2017
IPO Date Apr 14, 2022
Industry Medical Instruments & Supplies
Sector Healthcare
Employees 55
CEO Paul Danner

Contact Details

Address:
105 Maxess Road, Suite 124
Melville, New York 11747
United States
Phone 631 574 4436
Website sharpstechnology.com

Stock Details

Ticker Symbol STSS
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $4.25
CIK Code 0001737995
CUSIP Number 82003F309
ISIN Number US82003F3091
Employer ID 82-3751728
SIC Code 3841

Key Executives

Name Position
Paul Kruger Danner III Executive Chairman and Principal Executive Officer
Andrew R. Crescenzo CPA Chief Financial Officer
Yuwen Zhang Chief Investment Officer and Director
Ben Scheu Vice President of Sales
Frank Parrado Corporate Controller

Latest SEC Filings

Date Type Title
Nov 14, 2025 10-Q Quarterly Report
Nov 12, 2025 SCHEDULE 13G/A Filing
Oct 31, 2025 D Notice of Exempt Offering of Securities
Oct 23, 2025 S-3 Registration statement under Securities Act of 1933
Oct 15, 2025 8-K Current Report
Oct 9, 2025 8-K Current Report
Oct 7, 2025 8-K Current Report
Oct 6, 2025 8-K Current Report
Oct 3, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Sep 29, 2025 8-K Current Report